Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-27T11:56:29.089Z Has data issue: false hasContentIssue false
  • English
  • Français

The current role of systemic therapy in the management of Malignant Melanoma of the skin: a literature review

Published online by Cambridge University Press:  05 December 2005

Elizabeth Reeves ,
P. Bridge  and
R. M. Appleyard
Elizabeth Reeves
Affiliation:
E. T. R., BSc Hons Radiotherapy and Oncology;
P. Bridge
Affiliation:
Sheffield Hallam University, Faculty of Health and Well-being, Sheffield, UK
R. M. Appleyard
Affiliation:
Sheffield Hallam University, Faculty of Health and Well-being, Sheffield, UK
Get access Rights & Permissions [Opens in a new window]

Abstract

Melanoma patients can be split into two main categories that have different aims for treatment; localised disease with either intermediate or high-risk of recurrence after surgery, and metastatic disease. Over the past decade, there have been many clinical trials looking at improving the success rates for localised and metastatic melanoma with alternative systemic treatments, namely immunotherapy, biochemotherapy and vaccines. This literature review summarises the clinical trials for each form of systemic treatment in localised and metastatic melanoma and assesses the effectiveness of each by an evaluation and comparison of relevant clinical trials for each systemic modality. The main objective was to assess whether alternative forms of systemic therapy have improved the disease free and overall survival rates achieved with chemotherapy.

Keywords

Melanomaimmunotherapyvaccinechemotherapysurgeryinterferoninterleukin
Type
Original Article
Information
Journal of Radiotherapy in Practice , Volume 4 , Issue 4 , December 2005 , pp. 161 - 175
Copyright
© 2005 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)